SUBSCRIBE
SUBSCRIBE

Avenzo Therapeutics

NEWS
Pictured: Photo illustration featuring Avenzo Therapeutics CEO Athena Countouriotis
Flush With New $150M Investment, Avenzo Pursues Licensing Strategy
Avenzo’s founders, who led Turning Point through its $4.1 billion sale to BMS, want to in-license three clinical-stage oncology candidates by early 2026.
April 2, 2024
 · 
3 min read
 · 
Neil Versel
Pictured: a cancer therapeutics collage/Nicole Bea
Avenzo Closes $150M Oversubscribed Series A-1 to Advance Cancer Therapies
Avenzo Therapeutics on Tuesday said it will use the financing round to advance its next-generation oncology pipeline, including a potentially best-in-class CDK2 selective inhibitor.
March 27, 2024
 · 
2 min read
 · 
Tristan Manalac
IN THE PRESS
Press Releases
Avenzo Therapeutics Announces $60 Million Series B Financing
September 23, 2025
 · 
2 min read
Press Releases
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
September 3, 2025
 · 
2 min read
Press Releases
Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate
July 8, 2025
 · 
2 min read
Press Releases
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor
June 5, 2025
 · 
2 min read
Press Releases
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate
June 3, 2025
 · 
2 min read
Press Releases
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate
May 22, 2025
 · 
2 min read
Press Releases
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor
May 22, 2025
 · 
2 min read
Press Releases
Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
January 7, 2025
 · 
3 min read
Press Releases
Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director
November 20, 2024
 · 
2 min read
Press Releases
VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
November 18, 2024
 · 
3 min read
Load More
JOBS